Show simple item record

dc.contributor.authorPopat, S
dc.contributor.authorHsia, T-C
dc.contributor.authorHung, J-Y
dc.contributor.authorJung, HA
dc.contributor.authorShih, J-Y
dc.contributor.authorPark, CK
dc.contributor.authorLee, SH
dc.contributor.authorOkamoto, T
dc.contributor.authorAhn, HK
dc.contributor.authorLee, YC
dc.contributor.authorSato, Y
dc.contributor.authorLee, SS
dc.contributor.authorMascaux, C
dc.contributor.authorDaoud, H
dc.contributor.authorMärten, A
dc.contributor.authorMiura, S
dc.date.accessioned2022-05-27T14:45:23Z
dc.date.available2022-05-27T14:45:23Z
dc.identifier.citationThe oncologist, 2022, 27 (4), pp. 255 - 265en
dc.identifier.issn1083-7159
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5159
dc.identifier.eissn1549-490Xen_US
dc.identifier.eissn1549-490X
dc.identifier.doi10.1093/oncolo/oyac022en_US
dc.identifier.doi10.1093/oncolo/oyac022
dc.description.abstract<h4>Background</h4>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard of care for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) with common mutations (Del19 or L858R); however, 7%-23% of NSCLC tumors harbor uncommon EGFR mutations. These mutations are highly heterogeneous, and developments in detection techniques are helping to identify mutations with little or no clinical data.<h4>Patients and methods</h4>In this retrospective, global, multi-center study (NCT04179890), existing health records were identified for consecutive EGFR TKI-naïve patients with uncommon EGFR mutations (T790M, ex20ins, major uncommon [G719X, L861Q, or S768I], or "other" mutations; compound mutations) treated with erlotinib, gefitinib, afatinib, or osimertinib in first or second line. Endpoints included time-to-treatment failure (TTF), objective response rate (ORR), and overall survival (OS).<h4>Results</h4>Overall, 246 patients (median age: 69.5 years; Asian: 84%) were included from 9 countries. Most patients (92%) received an EGFR TKI as first-line therapy; 54%, 43% and 3% received afatinib, first-generation TKIs, and osimertinib, respectively. Median TTF and OS with EGFR TKIs were 9.9 and 24.4 months; ORR was 43%. In patients treated with first-line chemotherapy (n = 20), median TTF and ORR were 6.6 months and 41%. Outcomes were most favorable in patients with major uncommon or compound mutations. Overall, TTF was 11.3 months with afatinib and 8.8 months with first-generation EGFR TKIs across mutation categories. In most mutation categories, median OS was >2 years.<h4>Conclusion</h4>In a real-world setting, EGFR TKIs were the preferred treatment option in patients with uncommon EGFR mutations; strongest outcomes were seen in patients with major uncommon and compound mutations.en_US
dc.formatPrinten_US
dc.format.extent255 - 265en_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectHumansen_US
dc.subjectCarcinoma, Non-Small-Cell Lungen_US
dc.subjectLung Neoplasmsen_US
dc.subjectProtein Kinase Inhibitorsen_US
dc.subjectRetrospective Studiesen_US
dc.subjectCohort Studiesen_US
dc.subjectMutationen_US
dc.subjectAgeden_US
dc.subjectErbB Receptorsen_US
dc.titleTyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).en
dc.typeJournal Article
dcterms.dateAccepted2021-12-03
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.1093/oncolo/oyac022en
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en
dc.relation.isPartOfThe oncologisten_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-statusPublisheden_US
pubs.volume27en_US
pubs.embargo.termsNot knownen_US
icr.researchteamThoracic Oncology
dc.contributor.icrauthorPopat, Sanjayen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/